November 10, 2019 at 1:33 pm

Vectura Group (LON:VEC) Given Buy Rating at Citigroup


Citigroup reiterated their buy rating on shares of Vectura Group (LON:VEC) in a research report report published on Thursday, ThisIsMoney.Co.Uk reports.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with's FREE daily email newsletter.

A number of other equities research analysts have also recently issued reports on VEC. Peel Hunt reiterated a hold rating on shares of Vectura Group in a research note on Monday, November 4th. Shore Capital reiterated a hold rating on shares of Vectura Group in a research note on Tuesday, September 10th. Two research analysts have rated the stock with a hold rating and four have assigned a buy rating to the company’s stock. Vectura Group has a consensus rating of Buy and a consensus price target of GBX 133.50 ($1.74).

VEC stock traded down GBX 3.20 ($0.04) during mid-day trading on Thursday, reaching GBX 84.50 ($1.10). The company had a trading volume of 736,225 shares, compared to its average volume of 4,610,000. The company has a quick ratio of 2.41, a current ratio of 2.84 and a debt-to-equity ratio of 1.73. The stock has a market capitalization of $529.16 million and a P/E ratio of -6.60. Vectura Group has a one year low of GBX 0.91 ($0.01) and a one year high of GBX 97.66 ($1.28). The stock’s 50-day simple moving average is GBX 85.54 and its two-hundred day simple moving average is GBX 81.13.

The firm also recently declared a dividend, which was paid on Friday, October 25th. Stockholders of record on Monday, October 14th were issued a dividend of GBX 6 ($0.08) per share. The ex-dividend date was Monday, October 14th.

About Vectura Group

Vectura Group plc engages in the design, development, and supply of pharmaceutical products for the treatment of airways-related diseases worldwide. The company's in-market products include Seebri Breezhaler and Neohaler, a DPI device and bronchodilator; AirFluSal Forspiro for the treatment of asthma and chronic obstructive pulmonary disease (COPD); Breelib for the treatment of pulmonary arterial hypertension; Relvar Ellipta/Breo Ellipta that is used in treating asthma and COPD; and Incruse Ellipta and Anoro Ellipta for the treatment of COPD.

Featured Article: What are the components of an earnings report?

Analyst Recommendations for Vectura Group (LON:VEC)

Leave a Comment

Your email address will not be published. Required fields are marked *